SEC Filings
Kraft Heinz Expects Adjusted Operating Profit To Fall In 2027 Despite A Second-Half Recovery
Higher turnaround spending has produced uneven results, while management targets expanding margins in 2028 and double-digit returns in 2029.
SEC Filings
Higher turnaround spending has produced uneven results, while management targets expanding margins in 2028 and double-digit returns in 2029.
SEC Filings
Liver-disease trials pushed development spending to $27.0 million, while the next FDA meeting is scheduled for December.
SEC Filings
Commercial-scale manufacturing validation is complete, with interim trial results and FDA pathway feedback expected in early 2027.
SEC Filings
Sales increased 11.8%, while nine-month care costs grew faster than revenue and debt stood at $1.5 billion.
SEC Filings
The company reached its debt target a quarter early and authorized up to $150 million in share repurchases.
SEC Filings
Lower staff and facility costs helped narrow the quarterly loss as Century prepares its cell therapies for human testing.
SEC Filings
Its fiscal 2027 sales forecast assumes $100 million from AI drug discovery, alongside a $75 million capital-spending plan.
SEC Filings
CARFAX sales grew 8%, while selling expenses and interest costs climbed in the company's first full standalone quarter.
SEC Filings
President Jason P. Ment will give more time to private-wealth, retirement-plan and insurance investment solutions.
SEC Filings
The Market Shaper designation assesses practical quantum computing ambitions, and Gartner says its ratings are opinions, not endorsements.
SEC Filings
The AI drug developer expects hair-regrowth results in December and appointed a former Galderma executive as commercial chief.
SEC Filings
Pediatric exclusivity would move licensed entry to 2040, while the settlement permits an earlier launch under certain circumstances.